{"product_id":"aod9604-30-mg-pen","title":"AOD9604 | 30 mg pen","description":"\u003cp class=\"p1\"\u003eOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone (hGH 176–191), studied for its role in lipid metabolism and adipose-tissue regulation. In research settings, it has been evaluated in models where lipolysis, fat-mass reduction, and metabolic efficiency are measured as endpoints. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eSupports\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eLipid metabolism assessed via lipolysis and fatty-acid mobilization markers.\u003cbr\u003eAdipose-tissue reduction endpoints tracked in body-composition research models.\u003cbr\u003eFat oxidation pathways studied through energy-utilization and metabolic flux frameworks.\u003cbr\u003eNon-IGF-1 fat-regulation mechanisms evaluated independently of growth signaling pathways.\u003cbr\u003eBody-weight and fat-mass changes measured in controlled metabolic studies.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eDESCRIPTION\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAOD-9604 is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone. It has been modified to isolate fat-metabolism signaling pathways while minimizing broader endocrine activity typically associated with full-length hGH. In experimental research, AOD-9604 has been studied for its ability to stimulate lipolysis and inhibit lipogenesis in adipose tissue. Unlike full growth hormone, it does not significantly elevate IGF-1 levels in most study models, making it relevant in metabolic research where growth-independent fat modulation is evaluated. AOD-9604 is presented here for controlled research and educational context only and is not marketed as a therapeutic intervention.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eCLINICAL STATUS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAOD-9604 has been evaluated in both preclinical and human clinical research settings, including studies focused on obesity and metabolic regulation. Outcomes in human trials have been variable and dependent on study design and dosing protocols. It is not widely approved as a general therapeutic product.\u003cbr\u003eEvidence type: Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ✘\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eMECHANISM OF ACTION\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eMechanistic models of AOD-9604 focus on its interaction with pathways involved in lipid metabolism. The peptide has been shown in research settings to stimulate lipolysis and inhibit the formation of new fat cells, particularly within adipose tissue. Unlike full-length growth hormone, AOD-9604 does not significantly activate IGF-1–mediated growth pathways, allowing selective targeting of fat metabolism. Effects are typically measured through changes in fat mass, lipid markers, and metabolic efficiency.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eBENEFITS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eTargeted Fat Metabolism Support: AOD-9604 has been studied for its ability to directly influence fat metabolism at the adipose-tissue level.\u003cbr\u003eLipolysis Stimulation: Experimental models show increased fat breakdown through activation of lipid-mobilization pathways.\u003cbr\u003eNon-IGF-1 Pathway Activity: Does not significantly elevate IGF-1 in most research settings, supporting growth-independent fat modulation.\u003cbr\u003eAdipose Tissue Reduction: Preclinical and clinical research has explored reductions in fat mass under controlled conditions.\u003cbr\u003eMetabolic Efficiency Research: Studies have evaluated improvements in fat utilization and energy metabolism.\u003cbr\u003eBody Composition Applications: Commonly used in research focused on fat loss, metabolic health, and body-composition outcomes.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eRESEARCH DATA\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eStudy\/model | Reported effect\u003cbr\u003eHuman obesity trials | Mixed results on fat reduction depending on protocol\u003cbr\u003eRodent metabolic models | Increased lipolysis and reduced fat accumulation\u003cbr\u003eIn vitro adipocyte studies | Inhibition of lipogenesis and stimulation of fat breakdown\u003cbr\u003eMetabolic pathway analysis | Changes in lipid utilization and energy markers observed\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eSTACK SUGGESTIONS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eGLP-1 analogues (appetite and metabolic pathway comparison frameworks)\u003cbr\u003eL-Carnitine (fatty-acid transport and oxidation studies)\u003cbr\u003eNAD+ (energy metabolism and mitochondrial function endpoints)\u003cbr\u003eStacks discussed are for experimental design only, not safety or efficacy guidance.\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003ePOSSIBLE SIDE EFFECTS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eInjection-site reactions including redness or discomfort\u003cbr\u003eMild metabolic adjustments depending on study protocols\u003cbr\u003eOccasional fatigue or transient systemic effects\u003cbr\u003eResponses vary depending on experimental conditions\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eSCIENTIFIC REFERENCES\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAOD-9604 obesity clinical trials — Human studies\u003cbr\u003eGrowth hormone fragment (176–191) metabolic research — Mechanistic studies\u003cbr\u003eAdipocyte lipolysis and lipogenesis regulation — In vitro data\u003cbr\u003eMetabolic pathway studies involving AOD-9604 — Preclinical research\u003c\/p\u003e\n\u003cp class=\"p2\"\u003e\u003cb\u003eCAUTIONS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"p3\"\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease. Not approved for general medical use. Outcomes vary based on experimental design and metabolic conditions. Consult a qualified professional for any health-related decisions.\u003c\/p\u003e","brand":"Peptoora","offers":[{"title":"Default Title","offer_id":61705691857226,"sku":null,"price":399.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/AOD9604_7e546e5d-9c12-4562-a9eb-d4e438e82017.png?v=1777102308","url":"https:\/\/peptoora.com\/es\/products\/aod9604-30-mg-pen","provider":"Peptoora LTD","version":"1.0","type":"link"}